FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844771852> ?p ?o ?g. }

• W1844771852 endingPage "4132" @default.
• W1844771852 startingPage "4123" @default.
• W1844771852 abstract "Abstract Purpose: Anaplastic thyroid cancer (ATC) is a rare but lethal malignancy without any effective therapy. The aim of this study is to use a high-throughput drug library screening to identify a novel therapeutic agent that targets dysregulated genes/pathways in ATC. ExperimentalDesign: We performed quantitative high-throughput screening (qHTS) in ATC cell lines using a compound library of 3,282 drugs. Dysregulated genes in ATC were analyzed using genome-wide expression analysis and immunohistochemistry in human ATC tissue samples and ATC cell lines. In vitro and in vivo studies were performed for determining drug activity, effectiveness of targeting, and the mechanism of action. Results: qHTS identified 100 active compounds in three ATC cell lines. One of the most active agents was the first-in-class survivin inhibitor YM155. Genome-wide expression analysis and immunohistochemistry showed overexpression of survivin in human ATC tissue samples, and survivin was highly expressed in all ATC cell lines tested. YM155 significantly inhibited ATC cellular proliferation. Mechanistically, YM155 inhibited survivin expression in ATC cells. Furthermore, YM155 treatment reduced claspin expression, which was associated with S-phase arrest in ATC cells. In vivo, YM155 significantly inhibited growth and metastases and prolonged survival. Conclusions: Our data show that YM155 is a promising anticancer agent for ATC and that its target, survivin, is overexpressed in ATC. Our findings support the use of YM155 in clinical trials as a therapeutic option in advanced and metastatic ATC. Clin Cancer Res; 21(18); 4123–32. ©2015 AACR." @default.
• W1844771852 created "2016-06-24" @default.
• W1844771852 creator A5005193665 @default.
• W1844771852 creator A5031438011 @default.
• W1844771852 creator A5040666076 @default.
• W1844771852 creator A5046576171 @default.
• W1844771852 creator A5058336229 @default.
• W1844771852 creator A5060590657 @default.
• W1844771852 creator A5065730749 @default.
• W1844771852 creator A5067744023 @default.
• W1844771852 creator A5075092404 @default.
• W1844771852 creator A5076916905 @default.
• W1844771852 creator A5081154325 @default.
• W1844771852 creator A5083283635 @default.
• W1844771852 creator A5088207607 @default.
• W1844771852 date "2015-09-14" @default.
• W1844771852 modified "2023-09-26" @default.
• W1844771852 title "Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer" @default.
• W1844771852 cites W1506007624 @default.
• W1844771852 cites W1582160034 @default.
• W1844771852 cites W1585598556 @default.
• W1844771852 cites W1856442813 @default.
• W1844771852 cites W1967710178 @default.
• W1844771852 cites W1978880915 @default.
• W1844771852 cites W1986172624 @default.
• W1844771852 cites W1998915601 @default.
• W1844771852 cites W2003285711 @default.
• W1844771852 cites W2003470307 @default.
• W1844771852 cites W2005341905 @default.
• W1844771852 cites W2025906248 @default.
• W1844771852 cites W2028869988 @default.
• W1844771852 cites W2035523654 @default.
• W1844771852 cites W2044715980 @default.
• W1844771852 cites W2065792728 @default.
• W1844771852 cites W2066757562 @default.
• W1844771852 cites W2068305806 @default.
• W1844771852 cites W2080959559 @default.
• W1844771852 cites W2081161751 @default.
• W1844771852 cites W2083530633 @default.
• W1844771852 cites W2087681835 @default.
• W1844771852 cites W2106241374 @default.
• W1844771852 cites W2122376329 @default.
• W1844771852 cites W2125326666 @default.
• W1844771852 cites W2133692708 @default.
• W1844771852 cites W2134493631 @default.
• W1844771852 cites W2139533680 @default.
• W1844771852 cites W2151052146 @default.
• W1844771852 cites W2155664945 @default.
• W1844771852 cites W2157897307 @default.
• W1844771852 cites W2163746397 @default.
• W1844771852 cites W2172124462 @default.
• W1844771852 cites W2408997947 @default.
• W1844771852 doi "https://doi.org/10.1158/1078-0432.ccr-14-3251" @default.
• W1844771852 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4573822" @default.
• W1844771852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25944801" @default.
• W1844771852 hasPublicationYear "2015" @default.
• W1844771852 type Work @default.
• W1844771852 sameAs 1844771852 @default.
• W1844771852 citedByCount "28" @default.
• W1844771852 countsByYear W18447718522016 @default.
• W1844771852 countsByYear W18447718522017 @default.
• W1844771852 countsByYear W18447718522018 @default.
• W1844771852 countsByYear W18447718522019 @default.
• W1844771852 countsByYear W18447718522020 @default.
• W1844771852 countsByYear W18447718522021 @default.
• W1844771852 countsByYear W18447718522022 @default.
• W1844771852 countsByYear W18447718522023 @default.
• W1844771852 crossrefType "journal-article" @default.
• W1844771852 hasAuthorship W1844771852A5005193665 @default.
• W1844771852 hasAuthorship W1844771852A5031438011 @default.
• W1844771852 hasAuthorship W1844771852A5040666076 @default.
• W1844771852 hasAuthorship W1844771852A5046576171 @default.
• W1844771852 hasAuthorship W1844771852A5058336229 @default.
• W1844771852 hasAuthorship W1844771852A5060590657 @default.
• W1844771852 hasAuthorship W1844771852A5065730749 @default.
• W1844771852 hasAuthorship W1844771852A5067744023 @default.
• W1844771852 hasAuthorship W1844771852A5075092404 @default.
• W1844771852 hasAuthorship W1844771852A5076916905 @default.
• W1844771852 hasAuthorship W1844771852A5081154325 @default.
• W1844771852 hasAuthorship W1844771852A5083283635 @default.
• W1844771852 hasAuthorship W1844771852A5088207607 @default.
• W1844771852 hasBestOaLocation W18447718521 @default.
• W1844771852 hasConcept C121608353 @default.
• W1844771852 hasConcept C126322002 @default.
• W1844771852 hasConcept C207001950 @default.
• W1844771852 hasConcept C2775975398 @default.
• W1844771852 hasConcept C2779761222 @default.
• W1844771852 hasConcept C2780256643 @default.
• W1844771852 hasConcept C502942594 @default.
• W1844771852 hasConcept C54355233 @default.
• W1844771852 hasConcept C55493867 @default.
• W1844771852 hasConcept C62112901 @default.
• W1844771852 hasConcept C71924100 @default.
• W1844771852 hasConcept C81885089 @default.
• W1844771852 hasConcept C86803240 @default.
• W1844771852 hasConcept C96232424 @default.
• W1844771852 hasConceptScore W1844771852C121608353 @default.
• W1844771852 hasConceptScore W1844771852C126322002 @default.

• next